Background: Vincristine-induced peripheral neuropathy (VIPN) is difficult to quantify in children. Objective: The study objective was to examine the reliability, validity, and clinical feasibility of several VIPN measures for use in children with acute lymphoblastic leukemia. Interventions/Methods: Children (n = 65) aged 1 to 18 years receiving vincristine at 4 academic centers participated in the study. Baseline and preYvincristine administration VIPN assessments were obtained using the Total Neuropathy ScoreYPediatric Vincristine (TNSB-PV), the National Cancer Institute Common Terminology Criteria for Adverse Events, the Balis grading scale, and the FACES Pain Scale. The TNS-PV scores (n = 806) were obtained over 15 weeks. Blood was obtained at several time points to quantify pharmacokinetic parameters. Results: Cronbach's ! for a reduced TNS-PV scale was .84. The TNS-PV scores correlated with cumulative vincristine dosage (r = 0.53, P = 0.01), pharmacokinetic parameters (r = 0.41, P = 0.05), and grading scale scores (r range = 0.46Y0.52, P = .01). FACES scores correlated with the TNS-PV neuropathic pain item (r = 0.48; P = .01) and were attainable in all ages. A 2-item V-Rex score (vibration and reflex items) was the most responsive to change (effect size = 0.65, P G 0.001). The TNS-PV scores were attainable in 95% of children 6 years or older. Conclusions: The TNS-PV is reliable and valid for measuring Measuring
VIPN. It is sensitive to change over time (15 weeks) and feasible for use in children 6 years or older. Implications for Practice: The TNS-PV may be a useful tool for assessing vincristine toxicity in children with acute lymphoblastic leukemia.
Vincristine-Induced Peripheral Neuropathy
Vincristine-induced peripheral neuropathy (VIPN) occurs in nearly all children receiving vincristine for acute lymphoblastic leukemia. 1, 2 It is characterized by progressive motor, sensory, and autonomic nerve damage due to dysfunction of A", A%, and C-fibers. 3 Microtubule structure disruption and subsequent neuronal axon dysfunction, as well as inflammatory processes, have been suggested as possible pathophysiologic mechanisms. 4Y6 Common VIPN signs and symptoms include numbness and tingling in the hands and feet with associated neuropathic pain, asymptomatic hyporeflexia, constipation, muscle weakness, and, less commonly, patient experience impaired balance, jaw pain, and orthostatic hypotension. 1, 2, 5, 7, 8 Refractory peripheral neuropathy and associated neuropathic pain are significant health problems due to their undeniable negative influence on functional status, patient safety, quality of life, and cost of care. 9Y12 In addition, VIPN often necessitates chemotherapy dose reductions, possibly compromising the efficacy of a potentially lifesaving treatment. Therefore, efforts to prevent or minimize VIPN are critically important.
Measuring VIPN and Pain in Children
Vincristine-induced peripheral neuropathy symptoms such as numbness, tingling, and neuropathic pain are difficult concepts for young children to describe, and few studies have focused on developing and testing ways to quantify these symptoms. Peripheral nerve damage can be partially quantified based on changes in nerve conduction velocity and amplitude, 1 but nerve conduction studies are not feasible for use as a standard VIPN measurement approach because of the cost, inconvenience, and discomfort associated with the testing. The current standard tool for assessment of toxicities from cancer treatmentYrelated neurotoxicity is the National Cancer Institute Common Terminology Criteria for Adverse Events grading scale; however, there is conflicting evidence supporting the scale's reliability and validity. 13Y17 Other chemotherapy-induced peripheral neuropathy measures have been evaluated for use in adult cancer populations, 18 but only 2 small pilot studies published by the same lead author were found reporting results of clinimetric testing of neuropathy measures for use in children. 19, 20 In the most recent study, a pediatric variant of the Total Neuropathy Score (Ped-mTNSB) was tested in 41 children aged 5 to18 years who were receiving vincristine or cisplatin as treatment for various cancers and in 41 gender-matched controls. 20 Using the Ped-mTNS, children were evaluated for the presence of neuropathyspecific subjective sensory, motor, and autonomic symptoms. The wording of the subjective symptom questions of Ped-mTNS was simplified to be appropriate for school-aged children. Physical examination approaches were used to assess light touch, pin, and vibration sensitivity; strength; and deep tendon reflexes. An important finding from the earlier (2009) study was that the adapted measure was feasible for use in children based on ease of use and adequate child comprehension of subjective symptom assessment questions. 19 Gilchrist and Tanner 20 reported data supporting satisfactory internal consistency and intrarater and interrater reliability (IRR). The validity of Ped-mTNS was supported based on predictable associations with scores from balance and manual dexterity tests and because of the measure's ability to distinguish between contrasting groups. Sensitivity and responsiveness to change over time were not evaluated in either study. In addition, children younger than 5 years did not participate. Very young children may be especially vulnerable to cumulative vincristine neurotoxicity given their inability to communicate symptoms that would typically lead to toxicity-averting dose reductions. Neuropathy-related neuropathic pain is particularly difficult to assess because children at any age may be unable to acknowledge or describe the specific pain characteristics that distinguish neuropathic from nociceptive pain. There are numerous behavioral and self-report pediatric pain assessment instruments with strong clinimetric properties. However, based on the findings of 2 systematic reviews and the national consensus guideline for pain assessment in children and adolescents arising from the Pediatric Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials, 21Y23 reliable and valid neuropathic pain measures for use in children have not been developed.
Because of the dearth of literature regarding pediatric VIPN and associated pain measurement to date, it is important that future research be focused in this area. Moreover, special emphasis should be placed on identifying simple approaches to identifying VIPN signs and symptoms in very young children, especially because most acute lymphoblastic leukemia diagnoses and subsequent treatment with vincristine occur before the age of 5 years. The development, clinimetric testing, and utilization of VIPN and associated neuropathic pain assessment tools address a major gap in the science to date and are consistent with one of the priority goals defined at the National Cancer Institute State-of-the-Science Meeting on Peripheral Neuropathy (March 2009). To address the current gap in pediatric VIPN measurement science, this article reports the results of a study evaluating the clinimetric properties of 4 measures: the revised Total Neuropathy ScoreYPediatric Vincristine (TNS-PV), the National Cancer Institute Common Terminology Criteria grading scale version 4.0, the Balis Pediatric Scale of Peripheral Neuropathies, and the FACES Pain Scale when used to assess VIPN in children with precursor B acute lymphoblastic leukemia receiving vincristine. The specific aims of the study were to examine the (1) sensitivity of all 4 measures, (2) internal consistency and IRR of the revised TNS-PV, (3) responsiveness to change of all 4 measures, (4) construct and convergent validity of all measures, and (5) clinical feasibility of the TNS-PV. The primary hypothesis was that there would be a statistically significant change in TNS-PV scores when comparing baseline to week 15 VIPN assessment data.
n Methods
Sample and Setting
This multisite trial was conducted at 4 academic medical centers: Indiana University School of Medicine/Riley Hospital for Children, the University of Michigan Comprehensive Cancer Center/Mott Children's Hospital, Vanderbilt University/Monroe Carell Jr Children's Hospital, and George Washington University/ Children's National Medical Center. Sixty-five children with newly diagnosed precursor B acute lymphoblastic leukemia aged 1 to 18 years who were receiving vincristine according to a Children's Oncology Group (COG) treatment trial (including AALL0232, AALL 0331, AALL08P1, or AALL0932) participated in the study. Exclusion criteria were (1) baseline (prior to first vincristine dosage) peripheral neuropathy score greater than grade 1 (per the National Cancer Institute Common Terminology Criteria version 4.0); (2) currently receiving erythropoietin, itraconazole, or vitamin supplements greater than 100% of the recommended daily allowance; (3) Down syndrome; (4) pregnant; or (5) history of a coexisting serious illness that would limit the ability to obtain neurologic assessments. All children received vincristine 1.5 mg/m 2 (capped at 2-mg maximum dose) as defined by the specific COG treatment protocols. Toxicity-based dose modifications were defined according to the specific COG protocol guiding the individual child's leukemia treatment.
Measures
Four measures were evaluated in this study, the TNS-PV, National Cancer Institute Common Terminology Criteria version 4.0 and Balis grading scales, and the FACES Pain Scale. The TNS-PV is a variant of the TNS. The TNS is a neuropathy measurement composite tool that has been utilized by neurologists to more accurately quantify peripheral neuropathy. It is the most comprehensive composite tool to have been tested in patients receiving neurotoxic chemotherapy. 16 ,24Y30 This multidimensional instrument can be used to assess the characteristics and location (distally vs proximally) of neuropathy symptoms, as well as the severity and location of several physical examination findings (signs). 26Y29 Specifically, the TNS quantifies subjective sensory, motor, and autonomic symptoms; pin and vibration sensation; muscle strength; reflexes; sensory and motor nerve conduction; and computerized quantitative sensory testing findings. 24 Evidence exists supporting the reliability and validity of shorter 4-and 5-item TNS variants for use in adults receiving taxanes and platinum. 16, 25 These abbreviated TNS variants exclude the nerve conduction and quantitative sensory testing items and retain items quantifying neuropathy signs and symptoms based on interview and physical examination findings. For the current study, a TNS variant previously tested in adults was further revised for use in children receiving vincristine (TNS-PV) ( Table 1 ). This instrument quantifies subjective numbness, tingling, and neuropathic pain proximal extension, vibration and temperature sensation, muscle strength, deep tendon reflexes, constipation (a common sign of autonomic neuropathy), and hoarseness/vocal cord function (an indicator of laryngeal nerve neuropathy). Given that the sample was composed of children, the pinprick sensation item was replaced with a temperature sensation item (both items assess small nerve fiber function) to eliminate pinprick testingYrelated discomfort. Raters used a 128-Hz weighted tuning fork to assess vibratory sensibility and temperature sensibility (the patient's ability to sense cold when the tuning fork is placed on the skin). Each TNS-PV item is scored using a 0-to 4-point scale; higher scores equate to more severe neuropathy. With the original TNS scoring criteria (form A), signs and symptoms experienced in the hands versus the feet are not differentiated. A patient with only feet symptoms could receive the same score as a patient with symptoms in the feet and hands. Because VIPN experienced in both the hands and feet represents worse neuropathy than when VIPN occurs in the feet alone, 5 the original TNS scoring approach may be less sensitive to detecting more severe VIPN based on the proximal extension of signs and symptoms as neuropathy worsens. Therefore, an alternative scoring approach (form B) was tested whereby the presence of both lower-and upper-extremity symptoms reflected more severe neuropathy than the presence of lower-extremity symptoms alone.
Two grading scales were used to rate sensory and motor neuropathy; the Balis Pediatric Scale of Peripheral Neuropathy, and the National Cancer Institute Common Terminology Criteria. The Balis instrument has been commonly used to grade neurotoxicity occurring in children and is based on a 0-to 4-point scale. The National Cancer Institute Common Terminology Criteria has been used extensively to quantify sensory and motor neurotoxicity occurring in adults participating in cancer treatment trials and is based on a 0-to 5-point scale. 31 For both scales, higher scores reflect worse neuropathy.
Vincristine-induced peripheral neuropathyYassociated neuropathicspecific pain was assessed using the FACES Pain Scale. The FACES Scale uses face drawings depicting increasing degrees of distress to correlate with increasing pain severity. 32 The faces are linked with a 0-to 5-point numerical response criterion: 0 = no hurt, 1 = hurts a little, 2 = hurts a little more, 3 = hurts even more, 4 = hurts a whole lot, and 5 = hurts the worst.
Approaches Used to Evaluate Clinimetric Properties
Neuropathy and pain measure sensitivity were judged based on whether the various measures detected a wide range of scores as opposed to revealing only scores at the low (floor effects) or high (ceiling effects) end of the scale range. Two types of TNS-PV reliability were evaluated. Internal consistency reliability was evaluated as a gauge of whether the individual TNS-PV items were measuring a similar construct. High item-to-item correlations would suggest that the instrument items were each measuring VIPN. 33 Interrater reliability was assessed to determine whether 2 different raters would obtain the same TNS-PV score (a measure of equivalence reliability). 34 Responsiveness was evaluated based on the instruments' ability to detect changes in neuropathy and pain over time as the children received increasingly higher cumulative vincristine dosages. The extent to which the TNS-PV would predictably quantify neuropathy and pain in relationship to other related constructs (vincristine dosage) or other measures of neuropathy and pain (the National Cancer Institute and Balis grading scales, and the FACES Pain Scale) was assessed (construct and convergent validity). Given that VIPN worsens as children receive higher and higher cumulative vincristine doses over time, construct validity would be supported if the neuropathy and pain scores obtained using the TNS-PV, grading scales, and FACES scale were positively correlated with vincristine cumulative dosage and a pharmacokinetic (PK) parameter of vincristine metabolism (area under the concentration time curve [AUC]). Evidence of convergent validity would be based on positive correlations between the TNS-PV and other neuropathy and pain measures. Lastly, because it is often difficult to quantify neuropathy in young children, the feasibility of using the TNS-PV within a pediatric setting was evaluated based on the proportion of unattainable neuropathy assessments because of a child's inability to appropriately cooperate with the assessment examination or to understand the concepts of vincristine-related numbness, tingling, and pain. 24,26 b Score is based on the worst of the 3 symptoms. c Toe extension/flexion, ankle dorsiflexion, hip flexion, hand grip, thumb abduction, wrist extension, arm abduction; score is based on the weakest muscle group.
Procedure
The study was reviewed and approved by each site's institutional review board. Upon meeting eligibility requirements, parental/ guardian consent and the child's assent (for children 7Y17 years of age) were obtained by the child's treating physician or by a study investigator. Vincristine-induced peripheral neuropathy and pain assessments were performed by trained evaluators at each site. Nonneurologist clinician evaluators (eg, nurses, midlevel providers, and physicians) and a pediatric neurologist from each study site were trained to perform the VIPN and pain assessments. Neurologic examination, pain assessment, and instrument scoring procedures were reviewed via face-to-face training sessions. All evaluators viewed a training video created specifically for use in this study. The training video was posted on a study-specific Web site to facilitate unlimited future access. After viewing the video and completing the face-to-face training, evaluators engaged in hands-on practice supervised by a study investigator (E.M.L.S.) and the site neurologist, first on individuals without VIPN and then on children with varying degrees of neuropathy. After the initial training session, site neurologists supervised any subsequent training of clinician evaluators at their respective institutions. Before conducting examinations for the study, each clinician evaluator conducted practice examinations on approximately 10 children with established peripheral neuropathy. Verbal permission to conduct the practice examination was obtained from the child and/or parent. After completing the 10 practice examinations, the site neurologist judged each evaluator's neurologic examination and TNS-PV scoring proficiency using a skills competency checklist. All evaluators had to score 100% in physical examination and instrument scoring competency before conducting formal study assessments.
The National Cancer Institute Common Terminology Criteria and Balis peripheral neuropathy grades were assigned by the patient's primary pediatric oncology provider (someone different than study staff ) on the same day that the TNS-PV score was obtained. Those grading neuropathy via a grading scale were blinded to TNS-PV scores. Likewise, trained neuropathy evaluators performing neuropathy assessments using the TNS-PV were blinded from grading scale scores.
Neuropathy and pain were evaluated at baseline (prior to day 8 vincristine) and on the day of each subsequent vincristine treatment. Assessments were conducted prior to vincristine administration. Each child was asked to rate pain in their hands, feet, or jaw, using the FACES Pain Scale. Additional data were collected regarding the vincristine M 2 and cumulative dosage received each week.
Population plasma PK sampling was performed in all weighing more than 10 kg. Four PK samples (20 mL) were collected from each patient. Samples from outpatients were collected before and at 5, 15, and 30 minutes after vincristine administration on day 8 of induction therapy. Four samples were also collected from inpatients 12 to 72 hours after vincristine administration. The vincristine PK parameters were initially estimated with a population PK model using the nonlinear mixed-effects model statistical software program. Then the AUCs for individual subjects were calculated based on the estimated PK parameters and vincristine dose.
Neurologist-nonneurologist evaluator IRR was assessed in 19 children who had received a minimum of 6 vincristine doses. Participants were assessed twice on the same day using the TNS-PV, once by the trained clinician evaluator and once by a neurologist. Raters were blinded to each other's findings.
Analyses
The primary hypothesis was that there would be a statistically significant change in the 7 TNS-PV individual item scores and the TNS-PV (A) total score, when comparing baseline to week 15 VIPN assessment data. The week 15 time point was selected because the greatest change in VIPN was expected to occur over this period, given that vincristine dose intensity (frequency of treatment) is the highest in the first 4 months of acute lymphoblastic leukemia therapy. The 7 TNS-PV (A) individual items were worst subjective symptom (A), temperature (A), vibration (A), reflexes, strength, autonomic/constipation, and laryngeal/ hoarseness. With 50 participants, there was 82% power to detect a 0.75 effect size (es), if the type I error was controlled at 0.6% per test, or 5% total divided by 8 (7 items plus the TNS-PV [A] total score). The ES is defined as the difference between the baseline and week 15 TNS-PV (A) item scores divided by the SD. Analyses were completed using SPSS for Windows (version 19.0; IBM Corporation, Armonk, New York) (2011). Descriptive statistics were used to assess demographic variables. Tests of normalcy revealed that scores from the TNS-PV and the Balis and National Cancer Institute Common Terminology Criteria grading scales were all positively skewed, meaning that scores were low on average. Therefore, in most cases, nonparametric Mann-Whitney tests and Spearman D correlations were used to analyze the data. However, given the large sample size used for some analyses, parametric (Pearson) correlations were also calculated, and when similar, the parametric results have been presented.
A TNS-PV item analysis was conducted by calculating individual item and total score means, ranges, SDs, and interitem correlations (aims 1 and 2). Internal consistency reliability was assessed using Cronbach's ! coefficients (aim 2). A value greater than .70 is considered adequate for a new measure. 33, 35 Total Neuropathy ScoreYPediatric Vincristine IRR was assessed using weighted 0 coefficients (using the Fleiss-Cohen quadratic weights) for the component scores (aim 2). 36 Mann-Whitney tests were used to evaluate each instrument's responsiveness to change over time, and ESs were calculated based on changes in VIPN and pain measure scores over time (from baseline to week 15) (aim 3). Correlation coefficients (Spearman D) were calculated to determine the associations between TNS-PV, Balis and National Cancer Institute Common Terminology Criteria, and the FACES scores, and cumulative vincristine dose and AUC (construct validity) (aim 4). Convergent validity was determined by assessing the correlations (Pearson) between TNS-PV and grading scale scores (Balis and National Cancer Institute Common Terminology Criteria version 4.0) and the correlation between the FACES Pain Scale scores and the TNS-PV neuropathic pain item scores (aim 4). Lastly, clinical
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n Results
Demographics
Data from 65 children were included in the analysis. Demographic data are presented in Table 2 . Thirty-four boys (52.3%) and 31 girls (47.7%) ranging in age from 2 to 18 years of age participated in the study. The mean age was 6.38 (SD, 4.4) years, and 46.2% were younger than 5 years. Most were white and non-Hispanic (87.5%) and were receiving vincristine treatment according to COG protocol AALL0932 (52.3%). The mean cumulative dosage received by week 15 was 12.6 (SD, 8.0) mg.
Item AnalysisVAims 1 and 2
Total Neuropathy ScoreYPediatric Vincristine (forms A and B) total and individual mean item scores, ranges, and SDs are presented in Table 3 . Mean individual TNS-PV (A and B) item scores ranged from 0.10 to 1.28 (SD range, 0.35Y1.30) (range, 787Y1064 assessments). The highest mean score was associated with the reflex item. All TNS-PV items encompassed the full score range (1Y4). When comparing form A to form B scores, means and SDs were slightly higher when using the form B scoring criteria. The TNS-PV (A) mean score was 3.18 (SD, 3.26), and total scores ranged from 0 to 21. The TNS-PV (B) mean score was 3.41 (SD, 3.58), and total scores ranged from 0 to 22. There was no statistically significant difference between forms A and B total scores.
The National Cancer Institute Common Terminology Criteria and Balis sensory and motor grading scale score means ranged from 0.27 to 0.38 (SD range, 0.63Y0.65). Only the Balis motor scale scores encompassed the full score range of 0 to 4. Common Terminology Criteria and Balis motor and sensory scores were low (0Y2) for approximately 98% of the sample, revealing a floor effect (most scores clustered at the lowest/floor end of the scale range). Common Terminology Criteria and Balis grade 3 neuropathy occurred in approximately 2%. The highest grading scale score (grade 4) was reported in only 1 patient using the Balis scale. FACES Pain Scale scores ranged from 0 to 5. The mean score was low at 0.19 (SD, 0.70) (n = 1037 assessments). Scores were attainable from all participating children, regardless of age.
Item-to-item correlations ranged from 0.003 (laryngeal/ hoarseness and numbness) to 0.44 (strength and vibration) ( Table 4 ). Moderately strong item-to-item correlations (r range = 0.51Y0.87) were found between the paresthesias, numbness, and neuropathic pain items and the worst symptom item, but this was expected because the worst symptom item score is in fact the score of the 3 subjective symptoms (ie, paresthesias, numbness, and neuropathic pain) that is the worst. Statistically significant correlations (P range = .01Y.05) were found between almost all items; however, the strength of the correlations were often low. For example, although the item-to-item correlations between the laryngeal (hoarseness) and autonomic (constipation) items and most other items were statistically significant, the correlations were all less than 0.13. Low item-to-item correlations suggest that the items in an instrument are not internally consistent/reliable (aim 2).
Internal Consistency ReliabilityVAim 2
! Coefficients were calculated for the 7-item TNS-PV variant and for a revised 5-item variant. The 5-item scale included worst subjective symptom, temperature, vibration, strength, and reflex items. The laryngeal and autonomic items were dropped from the 7-item TNS-PV variant because of suboptimal item-to-item correlations. In addition, the ! coefficient dropped significantly when these 2 items were included in the scale (! = .68). The ! coefficient for the 5-item TNS-PV (A) scale was .84, and form B ! was nearly identical. Despite the improved ! coefficient for the 5-item TNS-PV, all validity and responsiveness analyses were conducted using the original 7-item TNS-PV scores.
Interrater ReliabilityVAim 2
Acceptable TNS-PV IRR was demonstrated for nearly all TNS-PV (A and B) items. The TNS-PV scores obtained by trained raters correlated moderately strongly with neurologist TNS-PV scores (K w range = 0.54Y0.99) (n = 13Y19) with 1 exception; the paresthesia item IRR was poor (K w = 0.15). In nearly all cases, IRR was better when form B was used. (es range, 0.31Y0.66, P range = .006 to G.0001). Because the vibration and reflex items were the most responsive of all, a 2-item TNS-PV total score was computed (V-Rex). The simpler 2-item V-Rex (A and B) was the best/most responsive measure when compared with the 7-item TNS-PV (es = 0.65, P G .0001).
Responsiveness to Change Over TimeVAim 3

Construct ValidityVAim 4
Total Neuropathy ScoreYPediatric Vincristine (A) (7 item) construct validity was supported based on a moderately strong correlation with vincristine cumulative dosage (r = 0.53, P = .01) ( Table 6 ). Results were similar for other TNS-PV versions and therefore are not presented. Construct validity also is evidenced by a statistically significant correlation between TNS-PV (A) and vincristine AUC (r = 0.41, P = .05). The 2-item V-Rex was more strongly correlated with cumulative vincristine dose (r = 0.66, P = .01) and AUC (r = 0.50, P = .01) than the 7-item TNS-PV (A). Grading scale correlations with cumulative vincristine dosage were low (r range = 0.18Y0.35, P range not statistically significant to .05). There were no statistically significant associations between grading scale scores and AUC. 
Convergent ValidityVAim 4
Convergent validity is supported by moderately strong correlations between the TNS-PV (A) scores and the Common Terminology Criteria and Balis grading scale scores (r range = 0.48Y0.52, P = .01) ( Table 7) . Results were similar for other TNS-PV versions and therefore are not presented. The Common Terminology Criteria and Balis motor and sensory scales also were moderately to strongly correlated with each other (r range = 0.68Y0.90, P = .01). As expected, the FACES pain score was not highly correlated with TNS-PV (A), V-Rex, or grading scale scores (r range = 0.20Y0.38, P = .01), but it was moderately correlated with the neuropathic pain TNS-PV (A) subitem (r = 0.48, P = .01).
Feasibility of VIPN Assessment in Young ChildrenVAim 5
Vibration and temperature sensibility assessments could not be performed in 84% to 87% of children 3 years or younger (Figure 3 ). In addition, approximately 48% of 3-year-olds could not provide subjective symptom information regarding numbness, paresthesias, and neuropathic pain. However, reflex and strength scores were more easily attainable in this age group. Approximately 91% of reflex and 78% of strength scores, respectively, could be assessed in very young children, including strength of specific muscles such as big-toe dorsiflexion and extension of abductor pollicis brevis. Laryngeal and autonomic neuropathy assessments could be attained in nearly all children because changes in voice or bowel patterns could be observed by caregivers and/or clinical providers. Total Neuropathy ScoreY Pediatric Vincristine individual item assessments were attainable in nearly all children 6 years or older. Lastly, the FACES Pain Scale was answered by 95% of all aged children without parental assistance. However, some children required additional coaching so that they understood that their selected ''face'' should reflect pain severity in their hands, feet, or jaw versus general feelings of distress.
n Discussion
Vincristine is a mainstay treatment for a number of curable pediatric malignancies, including acute lymphoblastic leukemia. Although adequate vincristine dosing is correlated with im-proved survival, VIPN is a major cause of dose reductions. However, some children experience only mild VIPN, and thus, it is important that our assessment approaches can detect a broad range of VIPN severity. One could speculate that children with particularly high-risk disease who tolerate vincristine dose intensification (experience less severe VIPN) might benefit from better disease control by receiving higher doses of this important drug. Conversely, early or preemptive dose modification or even elimination of vincristine could be considered in children who are at high risk for severe VIPN. However, to effectively develop improved dosing algorithms, it is critical that we understand how VIPN signs and symptoms evolve over time. Based on an enhanced knowledge of VIPN severity and patterns, the next step should be to develop a system facilitating prediction of an individual child's risk and expected VIPN severity very early in (if not before initiating) therapy. A crucial step in this process of treatment optimization aimed at maximizing efficacy while minimizing the potential for severe adverse effects is to improve the ability to measure the clinical manifestations of toxicity (the phenotype). Williams et al 37 recently developed and reported the validity, reliability, and other psychometric properties of the Therapy-Related Symptom Checklist for Children (TRSC-C), a 30-item instrument that measures symptom occurrence and severity during pediatric cancer treatments; the sample included 385 children, 5 to 17 years old, 45% of whom had acute lymphoblastic leukemia. Numbness in the fingers/toes and jaw pain (adverse effects associated with vincristine treatment) were reported by 32% and 27% of the study participants, respectively. 37 These data illustrate that neuropathy is a commonly occurring problem in children with malignancy. Pain due to any cause (49%) and constipation (45%) occurred in a high percentage of the sample, 37 but it is not known whether these symptoms were directly related to vincristine therapy. Although this study provided important information regarding the clinimetric properties of a patient-reported symptom assessment measure, the TRSC-C should not be used to guide vincristine dosing. The TRSC-C does not quantify subclinical evidence of VIPN (detectable signs that emerge before a child will report symptoms) via assessment of vibration and reflexes and thereby will not assist the clinician to adjust vincristine dosages early enough in the treatment course. Therefore, when toxicity will be used to guide drug dosing, VIPN measures that are sensitive to early, subtle changes in the VIPN phenotype should be used. Capturing the neuropathy phenotype is challenging in patients of all ages; however, it is particularly difficult in children. Yet, given the great importance of vincristine in treatment of curable childhood cancers, as well as the significant potential to improve on our current use of this medication, we took on the challenge of modifying an assessment tool (TNS) to allow careful, noninvasive monitoring of children for VIPN. The current study is one of few to test the clinimetric properties of several VIPN objective and subjective assessment approaches for use in children. Our findings confirm results recently reported by Gilchrist and Tanner 20 in a study conducted in children receiving mainly vincristine (96%), where the majority of participants (56%) were receiving treatment for acute lymphoblastic leukemia. The researchers demonstrated that a slightly different version of the TNS was reliable and valid when used in children older than 5 years. 20 Although our findings support the reliability and validity of a TNS variant (TNS-PV), study findings also suggest that several assessment approaches were suboptimal based on poor sensitivity to detect subtle differences in signs and symptoms and suboptimal construct validity (grading scales) or an inability to pick up VIPN changes over time (several TNS-PV items). The temperature, vibration, and reflex items were the most responsive to change over time. Some of the individual TNS-PV items did not correlate with other TNS-PV items, suggesting that these poorly correlating items are not solely measuring VIPN. For example, autonomic/constipation scores did not correlate with other TNS-PV items. A plausible explanation for this low correlation is that although constipation is a common vincristine adverse effect, constipation results from other causes such as opioid use, as well as dietary and activityrelated factors. Assessing constipation is also complicated because oncologists and families often utilize prophylactic strategies, and although the TNS-PV asks about ''required'' management strategies, the difference between ''required'' versus ''prophylactic'' strategies is difficult to differentiate.
Most TNS-PV items were difficult to assess in very young children and therefore are not feasible for use in every child. Nearly all TNS-PV items were attainable in children 6 years or older. These findings suggest that clinicians could tailor their VIPN assessment approach based on the child's age. Children younger than 5 years may not be appropriate for studies requiring a clear VIPN phenotype. In addition, vincristine dose reductions for very young patients with discomfort or gait abnormality should be determined following a thorough clinical and neurologic evaluation. The most useful information gleaned from this research relates to how pediatric oncology clinicians can streamline their assessments in older children by using the V-Rex, a simple approach to VIPN assessment that provides far better information than the standard grading scaleYbased methods. Disadvantages of using the V-Rex are that a 2-item scale will generally demonstrate inferior internal consistency reliability when compared with scales with more items. Also, changes in weekly scores may be less obvious as evidenced by the more subtle V-Rex peaks and valleys when compared with the 7-item TNS-PV (A) score patterns (Figure 1) . Lastly, the FACES Pain Scale also was shown to be valid, sensitive, responsive, and feasible for use when quantifying VIPN-related pain severity in children of all ages. However, further research is needed to determine if the FACES scale specifically quantifies neuropathic as opposed to nociceptive pain, or if it could be assumed to characterize neuropathic pain once nociceptive sources have been ruled out in this population.
Although the TNS-PV forms A and B seem equivalent in terms of internal consistency reliability and validity, form B may be better because it more accurately reflects the distal-toproximal progression and thus will elucidate more severe neuropathy when compared with form A. As illustrated in Figure 1 , form A may underestimate neuropathy severity. This has important implications for minimizing neurotoxicity because vincristine dosing may be modified sooner when scoring VIPN using form B versus form A. In addition, IRR was better when using form B.
There are several study limitations that should be mentioned. First, caution should be taken in generalizing study findings to patients with neuropathy caused by other neurotoxic agents or to populations with no leukemia, because these conditions were not tested. The small sample sizes used to conduct some of the analyses may have resulted in inadequate power to detect statistically significant findings. Poor item-to-item correlations for the constipation and laryngeal items may have been influenced by data collection methods. Parents and/or children were asked to report constipation or hoarseness severity experienced a week or more in the past. Retrospective data of this nature are less valid. In addition, other factors, such as opioid use, could have influenced constipation incidence.
Another possible limitation has to do with the feasibility of translating these findings to clinical practice. Rigorous methods were used to train all neuropathy assessors located at several academic centers throughout the mid-and eastern United States. A train-the-trainer approach helped nurses, physician assistants, and hematologists to learn new VIPN assessment skills, and the scores obtained were similar to those obtained from pediatric neurologists. This suggests that broader implementation of the V-Rex assessment approach to community and academic settings is feasible, but may require some type of widespread educational effort, possibly offered at professional meetings.
In conclusion, the TNS-PV is a reliable and valid instrument for measuring vincristine-related neuropathy in children with leukemia. It is sensitive to change over time (15 weeks) and feasible for use in children 6 years or older. The main drawback of the 5-and 7-item TNS-PV is that scoring of most of its items is not possible when used in children younger than 5 years, and some of the individual items are not responsive to change over time. As an alternative, the simple 2-item V-Rex measure, combined with the FACES Pain Scale, could be used to assess VIPN in all children 6 years or older. Future consideration should be given to revising the TNS-PV scoring criteria to be more consistent with distal-to-proximal VIPN extension as neuropathy worsens. The National Cancer Institute Common Terminology Criteria and Balis scales have significant floor effects and therefore may underestimate VIPN severity. In addition, grading scale construct validity is inferior when compared with the TNS-PV.
Implications for Practice
As a means for optimizing chemotherapy efficacy while minimizing toxicity, an important goal will be to implement into clinical practice the use of sensitive, responsive, reliable, and valid tools to assess toxicities. The TNS-PV may be a useful tool for assessing vincristine toxicity in children with acute lymphoblastic leukemia.
